Macro and Strategy Research - The US economy is expected to maintain resilience due to Trump's tax cuts and tech capital expenditures, with the Fed likely to keep interest rates unchanged amid mixed signals on employment and inflation [2] - The Eurozone is experiencing weak recovery, with uncertainties stemming from geopolitical issues, particularly related to Greenland, which may affect economic stability [2] Domestic Economy - China's GDP growth in Q4 2025 slowed due to high base effects, but overall growth targets were met, with a stronger supply than demand and external demand outpacing internal demand [3] - High-frequency data suggests that exports may remain strong in early 2026, supported by tax policy adjustments and semiconductor industry performance, while domestic consumption faces challenges [3] - Investment is expected to gradually recover, driven by manufacturing and infrastructure investments, although the real estate sector remains cautious [3] Domestic Policy Environment - The People's Bank of China announced a package of structural monetary policies, indicating potential for further rate cuts and reserve requirement ratio reductions [3] - Fiscal policies, including interest subsidies and risk-sharing measures, are aimed at stimulating economic activity and improving corporate financing willingness [4] Fixed Income Research - The bond market has shown a strong oscillation, with the central bank injecting over 9 trillion yuan into the market, and MLF operations reaching 900 billion yuan [6] - The issuance of local government bonds has lengthened in duration, reflecting strategies to take advantage of low interest rates [6] - The bond market is expected to continue its oscillation, with inflation and monetary policy being key factors influencing market dynamics [7] Industry Research - The pharmaceutical industry is witnessing significant collaborations, such as the strategic partnership between CSPC Pharmaceutical and AstraZeneca for innovative long-acting peptide drug development [8] - The SW Pharmaceutical sector index shows a TTM P/E ratio of 51.60, with a valuation premium of 259% over the CSI 300 index [9] - Investment opportunities are identified in innovative drugs, CXO, and upstream life sciences, with a focus on AI applications in healthcare and pharmaceuticals [9]

Investment Rating - The report suggests focusing on innovative drugs, brain-computer interfaces, and AI medical applications, indicating a positive outlook for these sectors [1]. Core Insights - The pharmaceutical industry index decreased by 3.31% this week, underperforming the CSI 300 index by 3.39 percentage points. However, since the beginning of 2026, the pharmaceutical sector has increased by 3.14%, outperforming the CSI 300 by 1.49 percentage points [5][12]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 29.40 times, with a premium of 61.10% relative to the entire A-share market [22]. - Notable sub-sectors include blood products, which had the best performance this week with a decline of only 1.0%, while the top three performing sectors since the beginning of the year are hospitals (+12.0%), offline pharmacies (+9.3%), and medical R&D outsourcing (+6.7%) [28]. Summary by Sections Investment Strategy - The report highlights a robust combination of companies including 恒瑞医药 (Hengrui Medicine), 百济神州-U (BeiGene), 美好医疗 (Meihua Medical), and others, indicating their potential for growth and investment [19]. Market Performance - The pharmaceutical industry index's performance this week was ranked 23rd, while its year-to-date performance ranked 22nd among all sectors [5][20]. - The report notes that 60 stocks in the pharmaceutical sector had positive returns this week, while 420 stocks declined [35]. Company News - 先声药业 (Xiansheng Pharmaceutical) has authorized勃林格殷格翰 (Boehringer Ingelheim) for its drug SIM0709, with an upfront payment of €42 million and a total deal value of €1.058 billion [13]. - 石药集团 (Shijiazhuang Pharmaceutical) has partnered with 阿斯利康 (AstraZeneca) for a long-acting peptide project, which includes an upfront payment of $1.2 billion and potential milestone payments totaling $3.5 billion [14]. - 同源康 (Tongyuan Pharmaceutical) has its drug TY9591 included in the priority review list, expected to be launched in 2026, targeting EGFR mutation NSCLC brain metastasis patients [15]. Financial Data - The total market capitalization of the pharmaceutical industry is approximately ¥52,861.60 billion, with a circulating market value of ¥48,153.47 billion [3]. - The industry’s TTM PE ratio stands at 37.3, compared to the CSI 300's PE ratio of 14.2, indicating a significant premium for the pharmaceutical sector [3]. Additional Insights - The report emphasizes the importance of innovative drug development and strategic partnerships in driving growth within the pharmaceutical industry, particularly in the context of emerging therapies and technologies [1][19].

Core Viewpoint - AI is revolutionizing the life sciences and pharmaceutical research, significantly improving efficiency and reducing costs associated with drug development [3][4][7]. Group 1: Global AI Medical Market Expansion - The global AI medical market is rapidly expanding, characterized by the entry of major tech companies like NVIDIA, Google, and Microsoft, which are restructuring medical infrastructure [3][4]. - AI technology is deeply integrating with biotechnology, leading to unprecedented levels of financing and mergers in the AI medical sector, with projections indicating a record high in 2025 [4][5]. - Major pharmaceutical companies are investing billions in partnerships with AI startups, exemplified by Sanofi's $2.5 billion collaboration with Earendil and other significant deals with Atomwise and Dren Bio [5][6]. Group 2: AI Drug Development and Applications - AI is transforming drug development by addressing various diseases, including cancer, neurodegenerative diseases, metabolic disorders, autoimmune diseases, infectious diseases, and rare diseases, significantly lowering trial costs and improving success rates [7][8][9]. - The efficiency of AI in drug development is highlighted by its ability to reduce the traditional 10-year, $1 billion timeline with only a 10% success rate, enhancing the overall drug discovery process [8][9]. - AI's role in drug discovery is expanding from initial target identification to clinical trial design and patient recruitment, covering the entire industry spectrum [8][9]. Group 3: Policy Support for AI in Healthcare - National strategies are being implemented to support AI applications in healthcare, including the 2025 guidelines promoting AI in drug development to reduce costs and time [9][10]. - Local governments are providing financial incentives for AI drug development, with subsidies for computational costs and support for companies achieving regulatory approvals [11][12]. - Policies are encouraging the internationalization of innovative drugs, with significant support for local companies conducting global clinical trials [11][12]. Group 4: Future Opportunities in AI Healthcare - The first major opportunity lies in AI-assisted drug discovery, which is expected to have a trillion-dollar market potential, particularly in treating diseases like cancer and Alzheimer's [25][26]. - AI is set to enhance diagnostic accuracy in medical imaging, addressing resource distribution issues and integrating diagnostic capabilities into imaging devices [28][29]. - AI will drive advancements in clinical decision support and healthcare information systems, improving data utilization and patient care efficiency [30][31]. - AI-powered surgical robots are expected to redefine surgical precision and enable remote medical procedures, breaking geographical barriers in healthcare delivery [32][33].

证 券 研 究 报 告 行业周报 技术加持稳定原料药出口竞争力 医药行业周报 分析师：胡博新 SAC编号：S1050522120002 分析师：吴景欢 SAC编号：S1050523070004 医 药 行 业 观 点 2 诚信、专业、稳健、高效 请阅读最后一页重要免责声明 医 药 行 业 观 点 投资评级： 报告日期： 推荐 （ 维持 ） 2026年02月01日 1.技术加持稳定原料药出口竞争力，重视供给变量 根据医保商会数据，2025年中国医药保健品出口额1113.41亿美元，增长3.14%，其中西药原料出口额428.67亿美元，占西 药总出口的76.8%，同比微降0.27%。原料药出口能保持出口总量的相对稳定，是克服全球贸易变局和内部价格竞争内卷下 实现的，是中国原料药产业竞争力的体现。受关税贸易影响，2025年中国对美国医药出口下降了10.6%，而非美市场，欧 盟增长11.38%，新兴市场增长4.49%。展望2026年原料药贸易依然存在较多的不确定性，中国与印度之间原料药竞争合作 将进一步演绎。价格方面，价格竞争内卷是一方面，另一方面合成生物学等新技术加持，新工艺新产能的投产，单位成本 下降是重要一面。 ...

股票研究 /[Table_Date] 2026.02.01 持续推荐创新药械产业链 [Table_Industry] 医药 ——国泰海通医药 2026 年 2 月月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 谈嘉程(分析师) | 021-38038429 | tanjiacheng@gtht.com | S0880523070004 | 本报告导读： 持续推荐创新药械及产业链。 投资要点： | [Table_Invest] | | | --- | --- | | 评级： | 增持 | [Table_Report] 相关报告 医药《V940 五年随访数据披露，mRNA 肿瘤疫 苗长期价值验证》2026.01.30 医药《支持政策不断，持续推荐创新药械产业 链》202 ...

股票研究 /[Table_Date] 2026.02.01 持续推荐创新药械产业链 [Table_Industry] 医药 ——国泰海通医药 2026 年 2 月月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 谈嘉程(分析师) | 021-38038429 | tanjiacheng@gtht.com | S0880523070004 | 本报告导读： 持续推荐创新药械及产业链。 投资要点： | [Table_Invest] | | | --- | --- | | 评级： | 增持 | [Table_Report] 相关报告 医药《V940 五年随访数据披露，mRNA 肿瘤疫 苗长期价值验证》2026.01.30 医药《支持政策不断，持续推荐创新药械产业 链》202 ...

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector [5]. Core Insights - The report emphasizes the continuous focus on investment opportunities related to AI in healthcare, driven by the growth of Tencent's AI applications and the need for data-driven solutions in medical settings [2][21]. - The investment logic centers around "data closed-loop" and "scene demand," highlighting AI's role as a core productivity driver in healthcare under the dual pressures of cost control and technological advancements [22]. - The report outlines a three-stage clinical value investment strategy, focusing on innovative drug chains and medical devices, with specific recommendations for companies in these sectors [3][27]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index fell by 3.31%, underperforming the CSI 300 index by 3.39 percentage points and ranking 22nd among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index also declined by 2.98%, lagging behind the Hang Seng Index by 4.69 percentage points [1][15]. R&D Progress - Recent developments include new drug applications from companies such as Hengrui Medicine and Innovent Biologics, with ongoing clinical trials for various products [30]. Key Companies and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, recommending "Buy" for several firms including Innovent Biologics, WuXi AppTec, and Mindray Medical [4][27]. AI Healthcare Investment Focus - The report identifies several core areas for AI in healthcare, including AI drug development, medical imaging, chronic disease management, and surgical robotics, emphasizing the importance of proprietary data and business scenarios for competitive advantage [22][24]. Annual Investment Strategy - The report suggests that the investment focus should increasingly emphasize the clinical value of pharmaceuticals, with a positive outlook on innovative drug chains and high-end medical devices [3][26].

2026 年 02 月 01 日 证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 降息等多因素支持科研上游持续复苏，重点 推荐皓元医药、奥浦迈等 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025/2/5 2025/6/4 2025/10/1 2026/1/28 医药生物 沪深300 相关研究 《mRNA 疫苗龙头释放积极临床数据 信号，建议关注悦康药业、康希诺等》 2026-01-26 《JPM 2026 最前线观察：中国创新药 再次成为全球焦点！》 2026-01-18 东吴证券研究所 1 / 37 请务必阅读正文之后的免责声明部分 ◼ 本周、年初至今 A 股医药指数涨幅分别为-3.31%、3.14%，相对沪深 300 的超额收益分别为-0.56%、2.51%；本周、年初至今恒生生物科技指数 涨跌幅分别为-3.24%、8.76%，相对于恒生科技指数跑赢-1.87%、5.09%； ...

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 降息等多因素支持科研上游持续复苏，重点 推荐皓元医药、奥浦迈等 增持（维持） [Table_Tag] [Table_Summary] 投资要点 2026 年 02 月 01 日 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025/2/5 2025/6/4 2025/10/1 2026/1/28 医药生物 沪深300 相关研究 《mRNA 疫苗龙头释放积极临床数据 信号，建议关注悦康药业、康希诺等》 2026-01-26 《JPM 2026 最前线观察：中国创新药 再次成为全球焦点！》 2026-01-18 东吴证券研究所 1 / 37 请务必阅读正文之后的免责声明部分 ◼ 本周、年初至今 A 股医药指数涨幅分别为-3.31%、3.14%，相对沪深 300 的超额收益分别为-0.56%、2.51%；本周、年初至今恒生生物科技指数 涨跌幅分别为-3.24%、8.76%，相对于恒生科技指数跑赢-1.87%、5.09%； ...

2026.02.01 本文字数：3133，阅读时长大约5分钟 作者 |第一财经 王方然 1月30日，第一财经从香港证监会获悉，近期监管机构已通过通函要求上市保荐人迅速开展内部检讨， 并纠正招股文件准备中出现的严重缺失，包括文件质量不足、保荐人可能存在的失当行为及其资源管理 重大失误等。截至2025年12月31日，已有16宗港股上市申请被暂停审理。 2025年，港股IPO数量与募资额同比大幅跃升，排队企业已突破300家，市场热度持续攀升。然而，申 报文件质量下滑、保荐人资源不足、人才争夺激烈、费率竞争加剧等问题也随之显现。为此，此次香港 证监会在通函中表示，将密集推出多项针对性整改措施，涵盖从严审核标准、强化保荐人员与项目匹配 度披露要求、设定人员负荷上限等方面。 业内人士指出，随着2026年可能到来的新一轮IPO高峰及潜在的限售股解禁压力，香港资本市场正步入 一段机遇与挑战并存的关键时期。 上市激增引发质量隐忧 香港证监会在近期通函中指出，高度关注2025年新股申请激增期间暴露的问题，包括部分上市文件存在 严重缺失、保荐人可能行为失当及其资源管理出现重大疏漏。 第一财经注意到，2025年香港IPO市场呈现井喷 ...